Vaccine makers and vaccine manufacturers have been warned by a group of scientists that a recent report linking vaccines with cancer was misleading.
The report by the Institute of Medicine, which reviewed the work of researchers at the University of California, Los Angeles, found that some ingredients in the vaccine and some that are not contained in the final product are safe and do not pose a risk to people who have already been vaccinated.
The researchers also noted that the results were consistent with studies done in the past that suggested a protective effect of certain vaccines, including the DTaP and Gardasil vaccines.
The results also did not mean that all of the reported safety concerns were invalid, said the institute’s lead author, William Thompson, a professor of epidemiology at the Harvard School of Public Health.
“This is the first report that does not suggest that vaccines are causing cancer,” Thompson told reporters Thursday.
“But the results do suggest that it would be useful for vaccine makers to consider how the findings in the current study are related to prior studies.”
The institute’s report comes on the heels of a study released Thursday that found that a vaccine for the diphtheria-tetanus-pertussis (DTaP) vaccine that was administered in 2011 caused a doubling in cases of the coronavirus.
The vaccine has been the focus of a number of studies in recent years.
But the researchers who conducted the study say that the new data show that the vaccine did not cause an increase in cases.
The study was published in the peer-reviewed journal Science.
Vaccine safety The researchers reviewed the latest data from the Vaccine Safety Datalink, a database of studies of the safety of vaccines.
A recent analysis of the database found that, in the first six months after the first DTaM vaccine was distributed in the United States, the vaccine was linked to fewer deaths than if it had been administered as a four-dose schedule.
“There are significant risks associated with vaccination, including a possible increase in vaccine-induced immune responses and an increased risk of infection and death from the disease, and there are also significant risks of adverse effects, including increased morbidity and mortality,” the report said.
The institute also cited data that showed that the incidence of death from influenza-like illness rose after DTaMs were distributed in 2011 and after the vaccines were added to the schedule in 2014.
The group said that more research is needed before we can be confident that DTaPs have a vaccine-caused link to mortality.
But Dr. Michael Weiss, a clinical epidemiologist at Harvard Medical School who was not involved in the new research, said he was optimistic that the report would prompt a reassessment of the vaccine’s safety.
“I’m optimistic that this is the beginning of the end of the pandemic,” he said.
“The new evidence that we now have shows that there is a small but significant safety risk associated with the DTas, but we don’t know how much that risk is.”